BMEA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
BMEA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Biomea Fusion's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $135.31 Mil. Biomea Fusion's Total Assets for the quarter that ended in Mar. 2024 was $168.49 Mil.
The historical rank and industry rank for Biomea Fusion's Equity-to-Asset or its related term are showing as below:
During the past 5 years, the highest Equity to Asset Ratio of Biomea Fusion was 0.96. The lowest was -0.08. And the median was 0.89.
The historical data trend for Biomea Fusion's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biomea Fusion Annual Data | |||||||||||
Trend | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | ||||||
Equity-to-Asset | -0.08 | 0.08 | 0.96 | 0.84 | 0.85 |
Biomea Fusion Quarterly Data | ||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Equity-to-Asset | Get a 7-Day Free Trial | 0.74 | 0.90 | 0.89 | 0.85 | 0.80 |
For the Biotechnology subindustry, Biomea Fusion's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Biomea Fusion's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Biomea Fusion's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Biomea Fusion's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as
Equity to Asset (A: Dec. 2023 ) | = | Total Stockholders Equity | / | Total Assets |
= | 169.237 | / | 199.927 | |
= |
Biomea Fusion's Equity to Asset Ratio for the quarter that ended in Mar. 2024 is calculated as
Equity to Asset (Q: Mar. 2024 ) | = | Total Stockholders Equity | / | Total Assets |
= | 135.314 | / | 168.494 | |
= |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biomea Fusion (NAS:BMEA) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Thank you for viewing the detailed overview of Biomea Fusion's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.
Juan Pablo Frias | officer: Chief Medical Officer | 900 MIDDLEFIELD ROAD, 4TH FLOOR, C/O BIOMEA FUSION, INC., REDWOOD CITY CA 94063 |
A2a Pharmaceuticals, Inc. | 10 percent owner | 59 5TH AVE, NEW YORK NY 10003 |
Cormorant Asset Management, Lp | 10 percent owner | 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116 |
Bihua Chen | director, 10 percent owner | C/O CORMORANT ASSET MANAGEMENT, LP, 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116 |
Cormorant Global Healthcare Master Fund, Lp | 10 percent owner | 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116 |
Cormorant Private Healthcare Fund Iii Lp | 10 percent owner | 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116 |
Hitchcock Michael J.m. | director | C/O BIOMEA FUSION, INC., 726 MAIN STREET, REDWOOD CITY CA 94063 |
Franco Valle | officer: Chief Financial Officer | 999 SKYWAY ROAD, SUITE 150, SAN CARLOS CA 94070 |
Elizabeth Faust | director | C/O BIOMEA FUSION, INC., 900 MIDDLEFIELD RD., 4TH FL, REDWOOD CITY CA 94063 |
Sumita Ray | director | C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVENUE, SUNNYVALE CA 94085 |
Sotirios Stergiopoulos | director | C/O BIOMEA FUSION, INC., 726 MAIN STREET, REDWOOD CITY CA 94063 |
Rainer M Erdtmann | director, 10 percent owner, officer: President and COO | 1073 ARLINGTON BLVD., EL CERRITO CA 94530 |
Thomas Andrew Butler | director, 10 percent owner, officer: CEO | 726 MAIN STREET, REDWOOD CITY CA 94065 |
Eric Aguiar | director | 888 7TH AVENUE, 12TH FLOOR, NEW YORK NY 10106 |
Biomea Health, Llc | 10 percent owner | 726 MAIN STREET, REDWOOD CITY CA 94063 |
From GuruFocus
By sperokesalga sperokesalga • 05-02-2023
By Marketwired • 10-05-2023
By Marketwired • 06-21-2023
By Business Wire • 06-27-2023
By Marketwired • 08-31-2023
By Business Wire • 06-27-2023
By PRNewswire • 07-14-2023
By PRNewswire • 07-13-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.